Hematologic Emergencies in the PICU

Chapter

Abstract

The pediatric critical care physician is frequently challenged by hematologic abnormalities in critically ill children admitted to the pediatric intensive care unit (PICU). The challenge is to differentiate between primary hematologic emergencies that require critical care interventions and abnormalities secondary to other disease conditions. It is therefore necessary for the pediatric critical care physician to collaborate with the pediatric hematologist when managing such patients. This chapter summarizes some of the most common hematologic emergencies of red blood cell (RBC), white blood cell (WBC), or platelet disorders observed in critically ill children that may require attention of the pediatric critical care physician.

Keywords

Hematologic emergency Erythrocyte Platelets Sickle cell disease White blood cells 

References

  1. 1.
    Bateman ST, Lacroix J, Boven K, Forbes P, Barton R, Thomas NJ, et al. Anemia, blood loss, and blood transfusions in North American children in the intensive care unit. Am J Respir Crit Care Med. 2008;178:26–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Kneyber MC. Red blood cell transfusion in paediatric critical care. Clin Lab. 2011;57:263–6.PubMedGoogle Scholar
  3. 3.
    Sadowitz PD, Amanullah S, Souid AK. Hematologic emergencies in the pediatric emergency room. Emerg Med Clin North Am. 2002;20:177–98, vii.CrossRefPubMedGoogle Scholar
  4. 4.
    English M, Ahmed M, Ngando C, Berkley J, Ross A. Blood transfusion for severe anaemia in children in a Kenyan hospital. Lancet. 2002;359:494–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Lackritz EM, Campbell CC, Ruebush TK, Hightower AW, Wakube W, Steketee RW, et al. Effect of blood transfusion on survival among children in a Kenyan hospital. Lancet. 1992;340:524–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lackritz EM, Hightower AW, Zucker JR, Ruebush TK, Onudi CO, Steketee RW, et al. Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery. AIDS. 1997;11:1487–94.CrossRefPubMedGoogle Scholar
  7. 7.
    Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT study: anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004;32:39–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Kneyber MC, Hersi MI, Twisk JW, Markhorst DG, Plotz FB. Red blood cell transfusion in critically ill children is independently associated with increased mortality. Intensive Care Med. 2007;33:1414–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609–19.CrossRefPubMedGoogle Scholar
  10. 10.
    Rouette J, Trottier H, Ducruet T, Beaunoyer M, Lacroix J, Tucci M. Red blood cell transfusion threshold in postsurgical pediatric intensive care patients: a randomized clinical trial. Ann Surg. 2010;251:421–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Willems A, Harrington K, Lacroix J, Biarent D, Joffe AR, Wensley D, et al. Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Crit Care Med. 2010;38:649–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Rogers KL, Fey PD, Rupp ME. Coagulase-negative staphylococcal infections. Infect Dis Clin North Am. 2009;23:73–98.CrossRefPubMedGoogle Scholar
  13. 13.
    Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–9.CrossRefPubMedGoogle Scholar
  15. 15.
    McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011;18:158–65.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92:2551–5.PubMedGoogle Scholar
  17. 17.
    Liem RI, O’Gorman MR, Brown DL. Effect of red cell exchange transfusion on plasma levels of inflammatory mediators in sickle cell patients with acute chest syndrome. Am J Hematol. 2004;76:19–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome study group. N Engl J Med. 2000;342:1855–65.CrossRefPubMedGoogle Scholar
  20. 20.
    Zuckerman WA, Rosenzweig EB. Pulmonary hypertension in children with sickle cell disease. Expert Rev Respir Med. 2011;5:233–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Sullivan KJ, Kisson N, Goodwin RS. Sickle cell disease. In: Nicols DG, editor. Roger’s textbook of pediatric intensive care. 4th ed. Philadelphia: Wolter Kluwers Health; 2008. p. 1799–812.Google Scholar
  22. 22.
    Miller ST. How I, treat acute chest syndrome in children with sickle cell disease. Blood. 2011;117:5297–305.CrossRefPubMedGoogle Scholar
  23. 23.
    Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol. 2007;136:343–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Morris CR. Asthma management: reinventing the wheel in sickle cell disease. Am J Hematol. 2009;84:234–41.CrossRefPubMedGoogle Scholar
  25. 25.
    Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998;92:3082–9.PubMedGoogle Scholar
  26. 26.
    Bartram JL, Thein SL, Gardner K, Egberongbe Y, D’Silva P, Height SE, et al. Outcome of children with sickle cell disease admitted to intensive care - a single institution experience. Br J Haematol. 2010;150:614–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–94.PubMedGoogle Scholar
  28. 28.
    Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the cooperative study of sickle cell disease. J Pediatr. 2001;139:385–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42:699–704.CrossRefPubMedGoogle Scholar
  30. 30.
    Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78.CrossRefPubMedGoogle Scholar
  32. 32.
    Islam MS, Anoop P. Current concepts in the management of stroke in children with sickle cell disease. Childs Nerv Syst. 2011;27:1037–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev. 2004;1:CD003885.Google Scholar
  34. 34.
    Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol. 2010;25:2431–42.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bambauer R, Latza R, Schiel R. Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects. Ther Apher Dial. 2011;15:10–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Zager RA, Gamelin LM. Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol. 1989;256:F446–55.PubMedGoogle Scholar
  37. 37.
    Armutcu F, Gurel A, Hosnuter M, Pabuccu O, Altnyazar C. Caffeic acid phenethyl ester improves oxidative erythrocyte damage in a rat model of thermal injury. J Burn Care Rehabil. 2004;25:171–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Menestrina G, Serra MD, Prevost G. Mode of action of beta-barrel pore-forming toxins of the staphylococcal alpha-hemolysin family. Toxicon. 2001;39:1661–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Nizet V. Streptococcal beta-hemolysins: genetics and role in disease pathogenesis. Trends Microbiol. 2002;10:575–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French society of haematology. Lancet. 1996;348:573–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104:34–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–46.CrossRefPubMedGoogle Scholar
  44. 44.
    Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012;24:9–15.CrossRefPubMedGoogle Scholar
  45. 45.
    Hsiao AL, Baker MD. Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children. Curr Opin Pediatr. 2005;17:56–61.CrossRefPubMedGoogle Scholar
  46. 46.
    Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068–71.PubMedGoogle Scholar
  47. 47.
    Peters MJ, Ross-Russell RI, White D, Kerr SJ, Eaton FE, Keengwe IN, et al. Early severe neutropenia and thrombocytopenia identifies the highest risk cases of severe meningococcal disease. Pediatr Crit Care Med. 2001;2:225–31.CrossRefPubMedGoogle Scholar
  48. 48.
    van Deuren M, Neeleman C, Van ’t Hek LG, van der Meer JW. A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Med. 1998;24:157–61.CrossRefPubMedGoogle Scholar
  49. 49.
    McDonough J, Gruenwald C. The use of aprotinin in pediatric patients: a review. J Extra Corpor Technol. 2003;35:346–9.PubMedGoogle Scholar
  50. 50.
    Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010;24:249–73.CrossRefPubMedGoogle Scholar
  51. 51.
    Bolton-Maggs P, Tarantino MD, Buchanan GR, Bussel JB, George JN. The child with immune thrombocytopenic purpura: is pharmacotherapy or watchful waiting the best initial management? A panel discussion from the 2002 meeting of the American society of pediatric hematology/oncology. J Pediatr Hematol Oncol. 2004;26:146–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Division of Paediatric Intensive Care, Department of PaediatricsBeatrix Children’s Hospital, University Medical Centre Groningen, The University of GroningenGroningenThe Netherlands

Personalised recommendations